Benzinga – All hospital, biopharmaceutical and drug companies are likely to benefit from the U.S. healthcare reform, said the Barron’s weekly on Sunday.
Larry Feindberg, chief of Oracle Partners of Greenwich, Connecticut stated that the infusion of money into the healthcare system was likely to increase the growth rate and boost stock prices for many providers.
Feinberg said, the hopital operator Tenet Healthcare would see a rise from its $5.12 to $9.50 in the coming 12 months. He also said, Acorda Therapeutics will benefit from the approval of a new drug, and could be acquired at $50 per share. It presently stands at $21.73. Drug company Cephalon Inc’s could rise to $80 from $54.58 in the next 12 months.
